Meeting
2018 Gastrointestinal Cancers Symposium
Patterns of chemotherapy (CT) use in a U.S.-wide cohort of patients (pts) with metastatic gastric cancer (MGC).
Authors
Thomas Adam Abrams
Dana-Farber Cancer Institute, Boston, MA
Thomas Adam Abrams , Gary Meyer , Lisa M. Hess , Yajun Zhu , Sui Zhang , Astra M. Liepa , Jeffrey A. Meyerhardt , Deborah Schrag , Peter C. Enzinger , Charles S. Fuchs
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 112)
DOI
10.1200/JCO.2018.36.4_suppl.112
Abstract #
112
Poster Bd #
H16
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Comparison of efficacy and tolerance of first-line palliative chemotherapy EOX and mDCF regimens in patients with locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma without overexpression of HER2 receptors.
First Author: Sebastian Ochenduszko
Poster
2012 ASCO Annual Meeting
Tolerability and efficacy of a biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin regimen (TFOX) in previously advanced metastatic gastric and oesogastric junction (AGC) adenocarcinoma.
First Author: Simon Pernot
Poster
2020 Gastrointestinal Cancers Symposium
Survival benefit of conversion therapy after intensive chemotherapy for unresectable metastatic gastric cancer: A propensity score-matched analysis.
First Author: Hiroyuki Ohnuma
Poster
2018 Gastrointestinal Cancers Symposium
A comparison of doublet versus triplet chemotherapy regimens for esophagogastric adenocarcinoma (EGC): Is more always better?
First Author: Tiago Felismino